By Dennis Ford, Founder & CEO, LSN
Dr. William Kohlbrenner, CSO, LSN
Nature Magazine has published an article written by Dennis Ford (CEO) and Bill Kohlbrenner (CSO) that draws upon LSN’s expertise to provide practical guidance on capital raising for early stage life science companies.
If you are an aspiring entrepreneur spinning out a new biomedical technology or launching a biotech startup, one of your first tasks is to understand the funding process and how to tackle it. Five years ago, the accepted investment path was to write a proposal for Small Business Innovation Research (SBIR) grants, hit up a list of friends and family and canvass the local regional angel groups for ‘seed’ funding. After this first wave of funding, the next money was expected to come from venture capital (VC) entities or through collaborations with partnering companies.
What you need to know is that the world has changed, and the investor landscape has morphed.